Dupixent (dupilumab)

pCPA File Number: 23221

Negotiation Status:

Under consideration for negotiation

Indication(s):

Prurigo nodularis

Sponsor/Manufacturer:

Sanofi-Aventis Canada Inc.

CDA-AMC Project Number:

SR0876-000

pCPA Engagement Letter Issued:

Not Applicable

Negotiation Process Concluded:

Not Applicable